^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Brain Cancer

    Related cancers:
    Apply
    Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) (NCT07206849)
    Phase 2
    Nationwide Children's Hospital
    Not yet recruiting
    Last update posted :
    10/03/2025
    Initiation :
    03/01/2026
    Primary completion :
    03/01/2030
    Completion :
    03/01/2037
    BRAF
    |
    Ojemda (tovorafenib)
    DLL3 CAR-T Therapy Targeting Brain Tumors (NCT07180927)
    Phase 1/2
    Shenzhen Geno-Immune Medical Institute
    Recruiting
    Last update posted :
    09/18/2025
    Initiation :
    09/10/2025
    Primary completion :
    12/31/2028
    Completion :
    09/30/2029
    DLL3
    Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation (NCT07158710)
    Phase 1
    Haisco Pharmaceutical Group Co., Ltd.
    Recruiting
    Last update posted :
    09/08/2025
    Initiation :
    08/15/2025
    Primary completion :
    05/23/2029
    Completion :
    12/03/2029
    BRAF
    Asciminib With or Without Sildenafil for Brain Tumors (NCT07039760)
    Phase 1
    Washington University School of Medicine
    Not yet recruiting
    Last update posted :
    06/26/2025
    Initiation :
    12/01/2025
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    CRKL • ABL2
    |
    Scemblix (asciminib) • sildenafil
    FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration (NCT07004075)
    Phase 3
    Shanghai Fosun Pharmaceutical Industrial Develo...
    Not yet recruiting
    Last update posted :
    06/04/2025
    Initiation :
    06/30/2025
    Primary completion :
    04/30/2027
    Completion :
    04/30/2029
    BRAF
    |
    carboplatin • temozolomide • Ivesa (firmonertinib) • Fu Mai Ning (luvometinib) • vindesine
    Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma (NCT04661384)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    06/03/2025
    Initiation :
    03/05/2021
    Primary completion :
    11/17/2025
    Completion :
    11/17/2025
    CD123
    |
    MB-101
    Natural History Study of Patients With Neurofibromatosis Type I (NCT00924196)
    Phase N/A
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/25/2008
    NF1
    |
    NF1 mutation
    Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma (NCT05083754)
    Phase 1
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    08/31/2022
    Primary completion :
    01/01/2026
    Completion :
    01/01/2027
    PD-L1 • MSI • CD8 • PD-1 • CD4 • ICOS
    |
    temozolomide • carmustine • Zynyz (retifanlimab-dlwr)
    A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT) (NCT02637687)
    Phase 1/2
    Bayer
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/16/2015
    Primary completion :
    07/20/2024
    Completion :
    09/30/2026
    NTRK3 • ETV6 • NTRK
    |
    NTRK positive • NTRK fusion
    |
    carboplatin • Vitrakvi (larotrectinib) • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma (NCT04923126)
    Phase 1/2
    St. Jude Children's Research Hospital
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/21/2021
    Primary completion :
    06/01/2031
    Completion :
    06/01/2031
    BRAF • NF1 • PTPN11 • MYBL1
    |
    BRAF mutation
    |
    Gomekli (mirdametinib)
    A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations (NCT05588141)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    05/16/2023
    Primary completion :
    08/01/2025
    Completion :
    08/02/2029
    IDH1 • IDH2
    |
    IDH2 mutation
    |
    zotiraciclib (TG02)
    NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors (NCT01875601)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    06/11/2013
    Primary completion :
    09/08/2015
    Completion :
    09/08/2015
    CD4
    |
    cyclophosphamide • rhIL-15